Pharmacology of adenosine receptors: Recent advancements
F Vincenzi, S Pasquini, C Contri, M Cappello, M Nigro… - Biomolecules, 2023 - mdpi.com
Adenosine receptors (ARs) are widely acknowledged pharmacological targets yet are still
underutilized in clinical practice. Their ubiquitous distribution in almost all cells and tissues …
underutilized in clinical practice. Their ubiquitous distribution in almost all cells and tissues …
[PDF][PDF] A2A adenosine receptor agonists, antagonists, inverse agonists and partial agonists
Abstract The Gs-coupled A2A adenosine receptor (A2AAR) has been explored extensively
as a pharmaceutical target, which has led to numerous clinical trials. However, only one …
as a pharmaceutical target, which has led to numerous clinical trials. However, only one …
Population Pharmacokinetics of the Novel Adenosine A2A Antagonist/Inverse Agonist KW‐6356 and Its Active Metabolite Following Single and Multiple Oral …
T Tayama, H Okada, K Ogawa… - Clinical …, 2024 - Wiley Online Library
KW‐6356 is a selective antagonist and inverse agonist of the adenosine A2A receptor. The
primary aim of the present analysis was to characterize the pharmacokinetics (PK) of KW …
primary aim of the present analysis was to characterize the pharmacokinetics (PK) of KW …
How can caffeine alleviate the motor symptoms of Parkinson's disease?–the implications of adenosine 2A receptor antagonism
A Wójcik, A Górny, J Chwiejczak, J Młynarska… - Journal of Education …, 2024 - apcz.umk.pl
Introduction and purpose: Parkinson's disease (PD) is the second most common
neurodegenerative disease, mainly characterized by motor impairment with symptoms …
neurodegenerative disease, mainly characterized by motor impairment with symptoms …